Special Section on Medicines Development in China Focus on China

International Journal of Pharmaceutical Medicine

, Volume 20, Issue 6, pp 367-372

First online:

Human Subjects Protections in Clinical Drug Trials in China

A Focus on the Institute Level
  • Jiaqi XuAffiliated withDepartment of Drug Safety and Inspection, State Food and Drug Administration
  • , Benfu LiAffiliated withChinese Medical Ethics Association
  • , Qiang MaAffiliated withChinese Medical Ethics AssociationShanghai Health Bureau
  • , Haitao Heidi LiuAffiliated withForum for Ethical Review Committees in Asia and the Western Pacific (FERCAP)
  • , Yali CongAffiliated withMedical Ethics Program, Peking University Health Science Center Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


With the increasing number of clinical trials being undertaken in China over the last few years, stakeholders in human subjects protections (HSP) are facing many new challenges; currently, these challenges in HSP are largely taken up by the ethical review committees and study investigators. This article identifies a number of issues with the present system and suggests ways to resolve these issues at the institutional level. Though the Chinese government has developed a basic regulatory framework for HSP, further work still needs to be done.

It is imperative that China develops a robust and reliable HSP system at the institutional level as drug studies are increasingly being undertaken in mainland China.